Ovid Therapeutics Inc. (OVID)
Largest Insider Buys in Sector
OVID Stock Price History Chart
OVID Stock Performance
About Ovid Therapeutics Inc.
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment …
Insider Activity of Ovid Therapeutics Inc.
Over the last 12 months, insiders at Ovid Therapeutics Inc. have bought $50,364 and sold $0 worth of Ovid Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Ovid Therapeutics Inc. have bought $49,967 and sold $126,203 worth of stock each year.
Highest buying activity among insiders over the last 12 months: LEVIN JEREMY M (CEO) — $50,364.
The last purchase of 18,248 shares for transaction amount of $50,364 was made by LEVIN JEREMY M (CEO) on 2024‑03‑18.
List of Insider Buy and Sell Transactions, Ovid Therapeutics Inc.
| 2024-03-18 | CEO | 18,248 0.0261% | $2.76 | $50,364 | -56.78% | |||
| 2021-07-14 | Sale | President and CMO | 34,017 0.0508% | $3.71 | $126,203 | -10.93% | ||
| 2020-08-28 | CEO | 8,488 0.0143% | $5.84 | $49,570 | -33.90% | |||
| 2019-10-08 | 10 percent owner | 2M 4.1699% | $2.50 | $5M | +65.16% | |||
| 2019-10-08 | CEO | 60,000 0.1251% | $2.50 | $150,000 | +65.16% | |||
| 2019-02-26 | director | 10,000 0.0325% | $2.02 | $20,210 | +7.32% | |||
| 2019-02-22 | CEO | 75,000 0.2617% | $2.00 | $150,000 | +15.34% | |||
| 2018-08-14 | director | 20,000 0.0386% | $3.12 | $62,300 | -60.76% | |||
| 2018-08-14 | director | 10,000 0.0201% | $3.24 | $32,442 | -60.76% | |||
| 2017-08-25 | CEO | 30,668 0.062% | $3.58 | $109,638 | +20.31% |
Insider Historical Profitability
| LEVIN JEREMY M | CEO | 3616715 5.0933% | $0.97 | 5 | 0 | +33.6% |
| TAKEDA PHARMACEUTICAL CO LTD | 10 percent owner | 5750000 8.0975% | $0.97 | 1 | 0 | +65.16% |
| Bernstein Karen | director | 20000 0.0282% | $0.97 | 2 | 0 | <0.0001% |
| WILLIAMS DOUGLAS E | director | 5000 0.007% | $0.97 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Ecor1 Capital Llc | $18.66M | 8.62 | 6.12M | 0% | +$0 | 0.13 | |
| Helm Capital Management LLC | $16.21M | 7.49 | 5.32M | 0% | +$0 | 0.48 | |
| BlackRock | $12.8M | 5.91 | 4.2M | -2.88% | -$380,118.44 | <0.0001 | |
| Bvf Inc Il | $11.75M | 5.43 | 3.85M | -43.75% | -$9.14M | 0.09 | |
| Madison Avenue Partners, LP | $11.13M | 5.14 | 3.65M | 0% | +$0 | 1.82 |